Search results for "DEMENTIA"

showing 10 items of 542 documents

Recognition by familiarity is preserved in Parkinson's without dementia and Lewy-Body disease.

2010

Objective The retrieval deficit hypothesis states that the lack of deficit in recognition often observed in patients with Parkinson's disease is because of the low retrieval requirements of the task, given that these patients have retrieval and not encoding deficits. To test this hypothesis we investigated recognition memory by familiarity in Parkinson's patients and in patients with Lewy Bodies disease and Parkinson with dementia. Method We analyzed to what extent the experimental groups were able to recognize by familiarity in a typical yes/no recognition memory task. The experimental groups were patients with early nondemented Parkinson's disease, advanced nondemented Parkinson's disease…

Lewy Body Diseasemedicine.medical_specialtyParkinson's diseaseMatched-Pair AnalysisAudiologyCentral nervous system diseaseDegenerative diseaseReference ValuesmedicineDementiaHumansPsychiatryRecognition memoryAgedAnalysis of VarianceDementia with Lewy bodiesMemoriaCognitionParkinson DiseaseRecognition Psychologymedicine.diseaseNeuropsychology and Physiological PsychologyCase-Control StudiesMental RecallTrastorns de la memòria en la vellesaDementiaPsychologyNeuropsychology
researchProduct

The Italian dementia with Lewy bodies study group (DLB-SINdem): toward a standardization of clinical procedures and multicenter cohort studies design

2017

Dementia with Lewy bodies (DLB) causes elevated outlays for the National Health Systems due to high institutionalization rate and patients' reduced quality of life and high mortality. Furthermore, DLB is often misdiagnosed as Alzheimer's disease. These data motivate harmonized multicenter longitudinal cohort studies to improve clinical management and therapy monitoring. The Italian DLB study group of the Italian Neurological Society for dementia (SINdem) developed and emailed a semi-structured questionnaire to 572 national dementia centers (from primary to tertiary) to prepare an Italian large longitudinal cohort. The questionnaire surveyed: (1) prevalence and incidence of DLB; (2) clinical…

Lewy Body Diseasemedicine.medical_specialtyPediatricsDementia with Lewy bodieDementia with Lewy bodiesDermatologyCohort StudiesDiagnosis Differential03 medical and health sciences0302 clinical medicineQuality of lifeAlzheimer DiseaseSurveys and Questionnairesmental disordersStandardization of diagnostic proceduresDiagnosisDementia with Lewy bodies; Standardization of diagnostic procedures; Survey; Alzheimer Disease; Cohort Studies; Diagnosis Differential; Disease Management; Humans; Italy; Lewy Body Disease; Research Design; Surveys and Questionnaires; 2708; Neurology (clinical); Psychiatry and Mental HealthmedicineDementiaHumans030212 general & internal medicineSurveyMED/01 - STATISTICA MEDICAMED/26 - NEUROLOGIAbusiness.industryDementia with Lewy bodiesDisease ManagementStandardization of diagnostic procedureGeneral Medicinemedicine.diseaseSettore MED/26 - NEUROLOGIADementia with Lewy bodies; Standardization of diagnostic procedures; Survey; 2708; Neurology (clinical); Psychiatry and Mental HealthItalyResearch DesignPsychiatry and Mental HealthCohortDifferentialPhysical therapyDeliriumNeurology (clinical)Alzheimer's diseasemedicine.symptombusiness030217 neurology & neurosurgeryFrontotemporal dementiaCohort study2708
researchProduct

Measuring network disruption in neurodegenerative diseases: New approaches using signal analysis

2019

Advanced neuroimaging has increased understanding of the pathogenesis and spread of disease, and offered new therapeutic targets. MRI and positron emission tomography have shown that neurodegenerative diseases including Alzheimer’s disease (AD), Lewy body dementia (LBD), Parkinson’s disease (PD), frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) are associated with changes in brain networks. However, the underlying neurophysiological pathways driving pathological processes are poorly defined. The gap between what imaging can discern and underlying pathophysiology can now be addressed by advanced techniques that explore the cortical neural synchro…

Lewy Body Diseasemedicine.medical_treatmentElectroencephalographysurgery03 medical and health sciences0302 clinical medicineNeuroimagingAlzheimer DiseasemedicineDementiaHumans1506Amyotrophic lateral sclerosisNeurodegeneration030304 developmental biologyneurology (clinical)0303 health sciencesLewy bodymedicine.diagnostic_testbusiness.industryAmyotrophic Lateral Sclerosissurgery; neurology (clinical); psychiatry and mental healthMagnetoencephalographyElectroencephalographyNeurodegenerative DiseasesParkinson DiseaseMagnetoencephalographymedicine.diseaseTranscranial Magnetic Stimulation3. Good healthTranscranial magnetic stimulationpsychiatry and mental healthFrontotemporal DementiaNerve NetbusinessNeuroscience030217 neurology & neurosurgeryFrontotemporal dementiaJournal of Neurology, Neurosurgery, and Psychiatry
researchProduct

Assessing natural metalinguistic skills in people with Alzheimer’s disease and frontotemporal dementia

2019

Abstract Objective The aim of this paper is to assess whether the use of natural metalinguistic skills can be used to differentiate linguistic-communicative profiles of people with dementia (Alzheimer’s disease and frontotemporal dementia in the behavioural and primary progressive aphasia variants) in the earliest stages of the disease. Method A sample of 180 people was selected. Sixty had Alzheimer’s disease, 20 had frontotemporal dementia of the behavioural variant, and 40 had frontotemporal dementia of the primary progressive aphasia variant (20 had non-fluent primary progressive aphasia and 20 had semantic dementia). The control group was composed of 60 healthy people with ages, gender,…

Linguistics and LanguageCognitive NeuroscienceSemantic dementiaLinguisticsExperimental and Cognitive PsychologyDiseaseNeuropsychological TestsLPN and LVNmedicine.diseaseAdditional researchTest (assessment)Primary progressive aphasiaSpeech and HearingAphasia Primary ProgressiveAlzheimer DiseaseFrontotemporal Dementiamental disordersmedicineHumansDementiaInternal validityPsychologyFrontotemporal dementiaClinical psychologyJournal of Communication Disorders
researchProduct

The relationship between Polypharmacy and Trajectories of Cognitive Decline in People with Dementia: a large representative cohort study

2019

Polypharmacy, defined through the number of medications prescribed, has been linked to a range of adverse health outcomes in people with dementia. It is however unclear whether a numerical threshold of concurrently prescribed drugs is a suitable predictor for cognitive decline. We aimed to test associations between polypharmacy and both short-term (six months) and long-term (three years) cognitive trajectories in patients with incident dementia. Using data from a large mental health and dementia care database in South London, a cohort of 12,148 patients (mean age = 80.7 years, 61.1% female, mean MMSE = 18.6) clinically diagnosed with dementia was identified. We determined the number of medi…

Male0301 basic medicineGerontologyAgingCognitive declineBiochemistryCohort Studies03 medical and health sciencesCognitionCommunity care0302 clinical medicineEndocrinologyA large representative cohort study.- Experimental gerontology cilt.120 ss.62-67 2019 [Soysal P. Perera G. Isik A. Onder G. Petrovic M. Cherubini A. Maggi S. Shetty H. Molokhia M. Smith L. et al. -The relationship between polypharmacy and trajectories of cognitive decline in people with dementia]mental disordersGeneticsmedicineHumansDementiaCognitive DysfunctionCognitive declineassociations between polypharmacyMolecular BiologyAgedAged 80 and overPolypharmacypeople with dementia.Mini–Mental State Examinationmedicine.diagnostic_testbusiness.industryCognition; Cognitive decline; Community care; Dementia; PolypharmacyCognitionlong-term (three years)Cell BiologyMental Status and Dementia Testsmedicine.diseaseComorbidity030104 developmental biologyCohortPolypharmacyFemaleDementiabusinessshort-term (six months)030217 neurology & neurosurgeryCohort study
researchProduct

Impact of Resilience on the Association Between Amyloid-β and Longitudinal Cognitive Decline in Cognitively Healthy Older Adults

2019

The present study aims at investigating if the association between amyloid-β and longitudinal cognitive decline in cognitively healthy elderly is modulated by resilience capacity. Resilience capacity was quantified by education, which is a common proxy of resilience and has been shown to be related to a wide range of behaviors promoting resilience. Analyses were conducted with longitudinal cognitive data from the Alzheimer's Disease Neuroimaging Initiative (ADNI). 276 cognitively healthy older individuals (≥56 years) were included in the study. Baseline amyloid pathology was quantified using CSF amyloid-β 1-42 measurements. Longitudinal cognitive decline was assessed using ADAS13, Clinical …

Male0301 basic medicineGerontologyAmyloid pathologyAmyloid βClinical Dementia RatingDiseaseNeuropsychological Tests03 medical and health sciences0302 clinical medicineNeuroimagingAlzheimer Diseasemental disordersHumansMedicineCognitive DysfunctionLongitudinal StudiesCognitive declineAgedAged 80 and overAmyloid beta-Peptidesbusiness.industryGeneral NeuroscienceCognitionGeneral MedicineMiddle AgedResilience PsychologicalPeptide FragmentsPsychiatry and Mental healthClinical Psychology030104 developmental biologyMixed effectsFemaleGeriatrics and GerontologybusinessBiomarkers030217 neurology & neurosurgeryFollow-Up StudiesJournal of Alzheimer's Disease
researchProduct

Analysis of Functional and Cognitive Impairment in Institutionalized Individuals with Movement Disorders

2018

Background: Many neurological disorders lead to institutionalization and can be accompanied in their advanced stages by functional impairment, and progressive loss of mobility, and cognitive alterations. Objective: We analyzed the relationship between functional impairment and cognitive performance and its related subdomains in individuals with Parkinson’s disease, Alzheimer’s disease accompanied by motor dysfunction, and with other neurological disorders characterized by both motor and cognitive problems. Methods: All participants lived in nursing homes (Valencia, Spain) and underwent cognitive evaluation with the Mini-Mental State Examination; functional assessment of independence in act…

Male0301 basic medicineMovement disordersActivities of daily livingParkinson's diseaseEndocrinology Diabetes and MetabolismOverweight03 medical and health sciences0302 clinical medicinemedicineHomes for the AgedHumansImmunology and AllergyMemory impairmentCognitive DysfunctionEffects of sleep deprivation on cognitive performanceAgedAged 80 and overCognitive evaluation theoryMovement Disordersbusiness.industryInstitutionalizationCognitionMental Status and Dementia Testsmedicine.diseaseNursing Homes030104 developmental biologySpainFemalemedicine.symptombusiness030217 neurology & neurosurgeryClinical psychologyEndocrine, Metabolic & Immune Disorders - Drug Targets
researchProduct

Exosomal HSP70 for Monitoring of Frontotemporal Dementia and Alzheimer’s Disease: Clinical and FDG-PET Correlation

2019

We aimed to study the expression of circulating heat-shock protein HSP70 and exosomes in plasma of a cohort of patients with Alzheimer's disease (AD) and frontotemporal dementia (FTD) at different stages. We performed correlations with clinical scales and FDG-PET. HSP70 levels were higher within exosomes than free in plasma. Moderate correlations were found between exosomal HSP70 and CDR, FTLD-CDR, and extension of hypometabolism. Our results suggest modifications in the level of exosomal HSP70 during the course of neurodegeneration, regardless of AD or FTD, and therefore HSP70 could have a potential role in the follow-up of these disorders.

Male0301 basic medicineOncologymedicine.medical_specialtyDiseaseNeuropsychological TestsExosomesCorrelation03 medical and health sciences0302 clinical medicineAlzheimer DiseaseFluorodeoxyglucose F18Internal medicinemental disordersmedicineHumansHSP70 Heat-Shock ProteinsCorrelation of DataAgedbusiness.industryGeneral NeuroscienceNeurodegenerationGeneral Medicinemedicine.diseaseMicrovesiclesHsp70Psychiatry and Mental healthClinical Psychology030104 developmental biologyFrontotemporal DementiaPositron-Emission TomographyCohortFemaleRadiopharmaceuticalsGeriatrics and GerontologybusinessBiomarkers030217 neurology & neurosurgeryFrontotemporal dementiaJournal of Alzheimer's Disease
researchProduct

Frequency and Correlates of Subjective Memory Complaints in Parkinson’s Disease with and without Mild Cognitive Impairment: Data from the Parkinson’s…

2018

Subjective memory complaints (SMC) may represent the preclinical phase of mild cognitive impairment (MCI) due to Alzheimer's disease. Dementia/MCI have been described with a high prevalence in Parkinson's disease (PD), but whether SMC may predict the development of cognitive impairment has been barely explored. To evaluate the frequency and clinical correlates of isolated SMC (PD-SMC) or within the construct of MCI in subjects with PD, 147 PD patients from the PArkinson's disease COgnitive impairment Study (PACOS) were consecutively recruited for the study. This is a multicenter study involving two Movement Disorder Centers in south Italy. All subjects underwent comprehensive neuropsycholog…

Male0301 basic medicineParkinson's diseaseParkinson's diseaseDiseaseNeuropsychological TestsAnxietyLogistic regressionExecutive Function0302 clinical medicineSurveys and QuestionnairesAttentionCognitive impairmentAged 80 and overGeneral NeuroscienceNeuropsychologyParkinson DiseaseGeneral MedicineMiddle Agedmusculoskeletal systemPsychiatry and Mental healthClinical PsychologyVisual Perceptioncardiovascular systemAnxietySettore MED/26 - NeurologiaFemaleAnxiety; cognitive impairment; disability; motor impairment; Parkinson's disease; subjective complaints; Neuroscience (all); Clinical Psychology; Geriatrics and Gerontology; Psychiatry and Mental Healthmedicine.symptommedicine.medical_specialtyStatistics Nonparametricmotor impairment03 medical and health sciencesInternal medicinemental disordersmedicineHumansDementiaAgedRetrospective Studiescognitive impairmentSubjective complaints Cognitive Impairment Parkinson’s Disease Disability Motor Impairment AnxietyMemory DisordersNeuroscience (all)subjective complaintsbusiness.industrymedicine.diseaseCross-Sectional Studies030104 developmental biologydisabilityEtiologyGeriatrics and GerontologyCognition Disordersbusiness030217 neurology & neurosurgeryJournal of Alzheimer's Disease
researchProduct

Molecular properties underlying regional vulnerability to Alzheimer’s disease pathology

2018

Amyloid deposition and neurofibrillary degeneration in Alzheimer's disease specifically affect discrete neuronal systems, but the underlying mechanisms that render some brain regions more vulnerable to Alzheimer's disease pathology than others remain largely unknown. Here we studied molecular properties underlying these distinct regional vulnerabilities by analysing Alzheimer's disease-typical neuroimaging patterns of amyloid deposition and neurodegeneration in relation to regional gene expression profiles of the human brain. Graded patterns of brain-wide vulnerability to amyloid deposition and neurodegeneration in Alzheimer's disease were estimated by contrasting multimodal amyloid-sensiti…

Male0301 basic medicinePathologyphysiology [Amyloidogenic Proteins]genetics [Transcriptome]genetics [Alzheimer Disease]Cohort StudiesTranscriptomepathology [Alzheimer Disease]metabolism [Amyloidogenic Proteins]methods [Magnetic Resonance Imaging]0302 clinical medicinepathology [Brain]Gene expressiongenetics [Genetic Predisposition to Disease]Aged 80 and overmethods [Positron-Emission Tomography]NeurodegenerationBrainNeurofibrillary TanglesHuman brainMagnetic Resonance Imagingmetabolism [Neurofibrillary Tangles]medicine.anatomical_structureFemalemethods [Neuroimaging]Alzheimer's Disease Neuroimaging InitiativeAmyloidmedicine.medical_specialtyAmyloidmetabolism [Amyloid beta-Peptides]Amyloidogenic ProteinsNeuroimagingtau ProteinsBiology03 medical and health sciencesAlzheimer DiseasemedicineHumansDementiaGenetic Predisposition to Diseaseddc:610metabolism [Amyloid]AgedAmyloid beta-PeptidesCyclin-dependent kinase 5medicine.diseasemetabolism [tau Proteins]030104 developmental biologyPositron-Emission Tomographypathology [Neurofibrillary Tangles]Neurology (clinical)Transcriptome030217 neurology & neurosurgeryBrain
researchProduct